

References on Pau d'arco from Part 3 of

[Fighting Cancer with Plants from the Rainforest](#) by Leslie Taylor

The published research referenced in the book which is shown below includes the initials **HS**, **IVT**, **IVA**, **REV**, **INS**, and **NEW**. HS refers to research conducted in humans; IVT refers to *in vitro* research conducted inside of test tubes; IVA refers to *in vivo* research conducted in animals; REV refers to a review article that evaluated and summarizes multiple studies on the subject; INS refers to *in silico* research (newer computer modeling including molecular docking studies) and NEW refers new biological research methods which determine genes and signaling pathways, and molecular pathways of actions which were developed during and after the Human Genome Project discussed in chapter 5.

This research below was last updated in August 2025. To view research published after that time, follow this links to the National Institute of Health's National Library of Medicine on [Pau d'arco – *Tabebuia impetiginosa*](#) (*Tabebuia avellanedae*, *Handroanthus avellanedae*, *Handroanthus impetiginosus* refer to the same tree)

Cancer Research:

Human Clinical Trials:

Beg, M., et al. "708P - A phase I/Ib, multi-center trial of ARQ-761 (Beta-Lapachone) with gemcitabine/nab-paclitaxel in patients with advanced pancreatic cancer." *Ann. Oncol.* 2019 Oct; 30(5): v271. **(HS)**

Gerber, D., et al. "Phase 1 study of ARQ 761, a β -lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis." *Br. J. Cancer.* 2018 Oct; 119(8): 928-936. **(HS)**

Beg, M., et al. "Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer." *J. Surg. Oncol.* 2017 Jul; 116(1): 83-88. **(HS)**

Kim, S., et al. "Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H: quinone oxidoreductase 1: Two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials." *Drug Des. Devel. Ther.* 2017 Nov; 11: 3187-3195. **(HS)**

Giacomelli, I., et al. "Oral lapacho-based medication: an easy, safe, and feasible support to prevent and/or reduce oral mucositis during radiotherapy for head and neck cancer." *Nutr. Cancer.* 2015; 67(8): 1247-53. **(HS)**

Block, J., et al. "Early clinical studies with lapachol (NSC-11905)." *Cancer Chemother. Rep.* 1974; 4: 27-8. (HS)

Santana, C., et al. "Preliminary observation with the use of lapachol in human patients bearing malignant neoplasms." *Revista do Instituto de Antibioticos* 1971; 20: 61-8. (HS)

Rao, K., et al. "Recognition and evaluation of lapachol as an antitumor agent." *Canc. Res.* 1968; 28: 1952-54. (HS)

Reviews:

Mosquera-Morales, L., et al. "In vitro antiproliferative activity in plants of the genus *Tabebuia*: A systematic review. *Molecules*. 2025 May; 30(11): 2315. [\[Free Article\]](#) (REV)

Mahmoud, I., et al. "Anti-tumour signalling pathways and molecular targets of 1,4-naphthoquinone-based natural dyes." *Nat. Prod. Res.* 2025 Jul: 1-20.

Angulo-Elizari, E., et al. "Unlocking the potential of 1,4-naphthoquinones: A comprehensive review of their anticancer properties." *Euro. J. Med. Chem.* 2024 Feb; 268: 116249. [\[Free Article\]](#) (REV)

Khan, J., et al. "A review on the synthesis and application of naphthoquinone-based drugs." *Chemistry*. 2023 Dec; 6: 101138. [\[Free Article\]](#) (REV)

Rahman, M., et al. "Naphthoquinones and derivatives as potential anticancer agents: An updated review." *Chem. Biol. Interact.* 2022 Dec; 368: 110198. (REV)

Lima Bezerra, J., et al. "Anticancer potential and toxicity of the genus *Handroanthus mattos* (Bignoniaceae): A systematic review. *Toxicon*. 2022 Oct; 217: 131-142. (REV)

Gomes, C., et al. "Beta-lapachone: Natural occurrence, physicochemical properties, biological activities, toxicity and synthesis. *Phytochemistry*. 2021 Jun; 186: 112713. (REV)

Zhang, J., et al. "*Tabebuia impetiginosa*: A comprehensive review on traditional uses, phytochemistry, and immunopharmacological properties." *Molecules*. 2020 Sep; 25(18):4294. [\[Free Article\]](#) (REV)

Ferraz da Costa, D., et al. "Anticancer potential of resveratrol, β -lapachone and their analogues." *Molecules*. 2020 Feb; 25(4): 893. [\[Free Article\]](#) (REV)

Hussain, H., and Green, I. "Lapachol and lapachone analogs: a journey of two decades of patent research (1997-2016)." *Expert Opin. Ther. Pat.* 2017 Oct; 27(10): 1111-1121. (REV)

Pardee, A., et al. "Cancer therapy with beta-lapachone." *Curr. Cancer Drug Targets*. 2002 Sep; 2(3): 227-42. (REV)

Test Tube Studies on Multiple Cancer Cell Lines: (breast, liver, leukemia, large cell lung cancer)

Pires, T., et al. "Bioactive properties of *Tabebuia impetiginosa*-based phytopreparations and phytoformulations: A comparison between extracts and dietary supplements." *Molecules*. 2015 Dec; 20(12): 22863-71. (IVT)

Yamashita, M., et al. "Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, *Tabebuia avellanedae*." *Bioorg. Med. Chem.* 2009 Sep; 17(17): 6286-91. **(IVT)**
Colman de Saizarbitoria, T., et al. "Bioactive furonaphthoquinones from *Tabebuia barbata* (Bignoniaceae)." *Acta Cient. Venez.* 1997; 48(1): 42-6. **(IVT)**

Bladder Cancer:

Amparo, T., et al. "Beta-lapachone: effects on proliferation, survival, migration, cell cycle, and lncRNA modulation in bladder cancer cells with distinct TP53 profiles." *Drug Dev. Res.* 2025 Aug; 86(5): e70128. **(IVT, NEW)**
Ferreira, G., et al. "8-Methoxy- α -lapachone and lawsone: Antiproliferative effects on bladder tumour cells." *Nat. Prod. Res.* 2025 Mar; 39(5): 1058-1064. **(IVT, NEW)**
Lee, J., et al. "Beta-lapachone induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2 family and activation of caspases." *Exp. Oncol.* 2006 Mar; 28(1): 30-5. **(IVT, NEW)**

Brain Cancer:

Zhou, Y., et al. "Beta-lapachone attenuates BMSC-mediated neuroblastoma malignant transformation by inhibiting Gal-3/Gal-3BP/IL6 axis." *Front. Pharmacol.* 2021 Nov; 12: 766909. **(IVA, IVT, NEW)**
Xu, H., et al. "Inhibitory effects of lapachol on rat C6 glioma *in vitro* and *in vivo* by targeting DNA topoisomerase I and topoisomerase II." *J. Exp. Clin. Cancer Res.* 2016 Nov; 35(1): 178. **(IVA, IVT, NEW)**
Park, E., et al. " β -Lapachone-induced reactive oxygen species (ROS) generation mediates autophagic cell death in glioma U87 MG cells." *Chem. Biol. Interact.* 2011 Jan; 189(1-2): 37-44. **(IVT, NEW)**
Weller, M., et al. "Topoisomerase-I inhibitors for human malignant glioma: Differential modulation of p53, p21, Bax and Bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone." *Int. J. Cancer.* 1997 Nov; 73(5): 707-14. **(IVT)**

Breast Cancer:

Alum, E., et al. "Utilizing indigenous flora in East Africa for breast cancer treatment: an overview." *Anticancer Agents Med. Chem.* 2025; 25(2): 99-113. **(REV)**
Zada, S., et al. "Chlorogenic acid enhances beta-lapachone-induced cell death by suppressing autophagy in NQO1-positive cancer cells." *Cell. Biol. Int.* 2025 May; 49(5): 555-569.
Tumbath, S., et al. " β -Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers." *Oncoimmunology.* 2024 Jun; 13(1): 2363000. **(IVA, NEW)**

Calahorra, J., et al. "Unlocking the effective alliance of β -lapachone and hydroxytyrosol against triple-negative breast cancer cells." *Biomed. Pharmacother.* 2024 May; 174: 116439. **(IVT, NEW)**

Chang, M., et al. "Synergistic effect of β -lapachone and aminooxyacetic acid on central metabolism in breast cancer." *Nutrients.* 2022 Jul; 14(15): 3020. **(IVT, NEW)**

Telang, N., et al. "Growth inhibitory efficacy of *Tabebuia avellanedae* in a model for triple negative breast cancer." *Arch. Breast Cancer* 2021 Aug; 8(3): 203-209. **(IVA, IVT, NEW)**

Totten, S., et al. "STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer." *Nat. Commun.* 2021 Jun; 12(1): 3299.

Telang, N., et al. "Growth inhibitory efficacy and anti-aromatase activity of *Tabebuia avellanedae* in a model for post-menopausal luminal A breast cancer." *Biomed. Rep.* 2019 Nov; 11(5): 222-229. **(IVT, NEW)**

Zada, S., et al. "Protein kinase A activation by beta-lapachone is associated with apoptotic cell death in NQO1-overexpressing breast cancer cells." *Oncology Rep.* 2019; 42: 1621–1630.

Panda, S., et al. "Stem extract of *Tabebuia chrysantha* induces apoptosis by targeting EGFR in Ehrlich ascites carcinoma." *J. Ethnopharmacol.* 2019 Feb; 235: 219-226. **(IVA, IVT, NEW)**

Yang, Y., et al. " β -lapachone suppresses tumour progression by inhibiting epithelial-to-mesenchymal transition in NQO1-positive breast cancers." *Sci. Rep.* 2017 Jun; 7(1): 2681. **(IVA, IVT, NEW)**

Oliveira Silva, E., et al. "Cytotoxicity of lapachol metabolites produced by probiotics." *Lett. Appl. Microbiol.* 2014 Jul; 59(1): 108-14.

Garkavtsev, I., et al. "Dehydro-alpha-lapachone, a plant product with antivasular activity." *Proc. Natl. Acad. Sci. USA.* 2011 Jul; 108(28): 11596-601. **(IVA)**

Mukherjee, B., et al. "Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of *Tabebuia avellandae* tree." *Int. J. Mol. Med.* 2009 Aug; 24(2): 253-60. **(IVT, NEW)**

Queiroz, M., et al. "Comparative studies of the effects of *Tabebuia avellanedae* bark extract and beta-lapachone on the hematopoietic response of tumour-bearing mice." *J. Ethnopharmacol.* 2008 May; 117(2): 228-35. **(IVA, IVT)**

Cervical Cancer:

Du, P., et al. " β -lapachone suppresses carcinogenesis of cervical cancer via interaction with AKT1." *Front. Pharmacol.* 2025 Feb; 16: 1509568. **(IVA, IVT, NEW)**

Tokuda, H., et al. "Chemoprevention of herb tea, *Tabebuia avellanedae* on *in vitro* and *in vivo* carcinogenesis system." *Planta Med* 2012; 78: P1144. **(IVA, IVT, NEW)**

Balassiano, I., et al. "Demonstration of the lapachol as a potential drug for reducing cancer metastasis." *Oncol. Rep.* 2005; 13(2): 329-33. **(IVT)**

Colorectal Cancer:

Zhao, L., et al. "β-Lapachone induces ferroptosis of colorectal cancer cells via NCOA4-mediated ferritinophagy by activating JNK pathway." *Chem. Biol. Interact.* 2024 Feb; 389: 110866. (IVA, IVT, NEW)

Jung, E., et al. "β-Lapachone exerts anticancer effects by downregulating p53, lys-acetylated proteins, TrkA, p38, MAPK, SOD1, Caspase-2, CD44 and NPM in oxaliplatin-resistant HCT116 colorectal cancer cells." *Int. J. Mol. Sci.* 2023 Jun; 24(12): 9867. (IVT, NEW)

Kee, J., et al. "β-lapachone inhibits lung metastasis of colorectal cancer by inducing apoptosis of CT26 cells." *Integr. Cancer Ther.* 2017 Dec; 16(4): 585-596. (IVT, NEW)

Choi, B., et al. "Beta-Lapachone-induced apoptosis is associated with activation of caspase-3 and inactivation of NF-kappaB in human colon cancer HCT-116 cells." *Anticancer Drugs.* 2003 Nov; 14(10): 845-50. (IVT)

Huang, L., et al. "Beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells." *Mol. Med.* 1999 Nov; 5(11): 711-20. (IVT, NEW)

Fibrosarcoma:

Kim, J., et al. "Effect of lapachol on the inhibition of matrix metalloproteinase related to the invasion of human fibrosarcoma cells." *Curr. Mol. Pharmacol.* 2021 Oct; 14(4): 620-626. (IVT, NEW)

Gastric Cancer:

Yu, H., et al. "β-lapachone-induced apoptosis of human gastric carcinoma AGS cells is caspase-dependent and regulated by the PI3K/Akt pathway." *Biomol. Ther. (Seoul).* 2014 May; 22(3): 184-92. (IVT, NEW)

Head and Neck Cancers:

Dias, R., et al. "β-Lapachone and its iodine derivatives cause cell cycle arrest at G(2)/M phase and reactive oxygen species-mediated apoptosis in human oral squamous cell carcinoma cells." *Free Radic. Biol. Med.* 2018 Oct; 126: 87-100.

Jeon, Y., et al. "Downregulation of Sp1 is involved in β-lapachone-induced cell cycle arrest and apoptosis in oral squamous cell carcinoma." *Int. J. Oncol.* 2015; 46(6): 2606-12.

Sunasse, S., et al. "Cytotoxicity of lapachol, β-lapachone and related synthetic 1,4-naphthoquinones against esophageal cancer cells." *Eur. J. Med. Chem.* 2013 Apr; 62: 98-110.

Leukemia:

Guerrero-Pepinos, N., et al. "The n-butanol extract obtained from the inner bark of *Tabebuia rosea* (Bertol.) DC, specioside, and catalposide induce leukemia cell apoptosis in the presence of apicidin." *Molecules.* 2024 Aug; 29(17): 3986.

Zhang, J., et al. "Inhibition of thioredoxin reductase by natural anticancer candidate β -lapachone accounts for triggering redox activation-mediated HL-60 cell apoptosis." *Free Radic. Biol. Med.* 2022 Feb; 180: 244-252. **(IVT, NEW)**

de Andrade, J., et al. "Anticancer activity of β -Lapachone derivatives on human leukemic cell lines." *Chem. Biol. Interact.* 2022 Sep; 365: 110057. **(IVT, NEW)**

Marques, L., et al. "Lapachol acetylglycosylation enhances its cytotoxic and pro-apoptotic activities in HL60 cells." *Toxicol. In Vitro.* 2020 Jun; 65: 104772. **(IVT, NEW)**

Inagaki, R., et al. "Synthesis and cytotoxicity on human leukemia cells of furonaphthoquinones isolated from *Tabebuia* plants." *Chem. Pharm. Bull.* 2013; 61(6): 670-3. **(IVT, NEW)**

Salustiano, E., et al. "Comparison of the cytotoxic effect of lapachol, alpha-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells." *Invest. New Drugs.* 2010 Apr; 28(2): 139-44. **(IVT, NEW)**

Moon, D., et al. "Beta-lapachone (LAPA) decreases cell viability and telomerase activity in leukemia cells: suppression of telomerase activity by LAPA." *J. Med. Food.* 2010 Jun; 13(3): 481-8. **(IVT, NEW)**

Queiroz, M., et al. "Comparative studies of the effects of *Tabebuia avellanedae* bark extract and beta-lapachone on the hematopoietic response of tumour-bearing mice." *J. Ethnopharmacol.* 2008 May; 117(2): 228-35. **(IVA, IVT, NEW)**

Planchon, S., et al. "Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: A p53-independent response." *Cancer Res.* 1995 Sep; 55(17): 3706-11. **(IVT)**

Schuerch, A., et al. "B-Lapachone, an inhibitor of oncornavirus reverse transcriptase and eukarotic DNA Polymerase- α . Inhibitory effect, thiol dependency and specificity." *Eur. J. Biochem.* 1978; 84: 197-205. **(IVT)**

Linardi, M., et al. "A lapachol derivative active against mouse lymphocyte leukemia P-388." *J. Med. Chem.* 1975; 18(11): 1159-62. **(IVA)**

Liver Cancer:

Zhao, W., et al. " β -lapachone selectively hepatocellular carcinoma cells by targeting NQO1 to induce extensive DNA kills damage and PARP1 hyperactivation." *Front. Oncol.* 2021 Oct; 11: 747282. **(IVA, IVT)**

Park, E., et al. " β -Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells." *Cell Death Dis.* 2014 May; 5(5): e1230. **(IVT, NEW)**

Kim, S., et al. "Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of beta-lapachone in human hepatocarcinoma cells." *Biosci. Biotechnol. Biochem.* 2007 Sep; 71(9): 2169-76. **(IVT)**

Woo, H., et al. "Beta-lapachone, a quinone isolated from *Tabebuia avellanedae*, induces apoptosis in HepG2 hepatoma cell line through induction of Bax and activation of caspase." *J. Med. Food*. 2006 Summer; 9(2): 161-8. (IVT)

Lung Cancer:

Chen, Y., et al. "β-Lapachone, an NQO1 bioactivatable drug, prevents lung tumorigenesis in mice." *Eur. J. Pharmacol*. 2024 Jun; 973: 176511. (IVA, NEW)

Zhang, Z., et al. "Lapachol inhibits the growth of lung cancer by reversing M2-like macrophage polarization via activating NF-κB signaling pathway." *Cell. Signal*. 2023 Dec; 112: 110902. (IVA, IVT, NEW)

Li, J., et al. "The cancer stemness inhibitor napabucasin suppresses small cell lung cancer growth through SOX2 expression." *Am. J. Cancer Res* 2022 Oct; 12(10): 4637-4651. (IVA, IVT, NEW)

Ma, X., et al. "Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy." *J. Control Release*. 2015 Feb; 200: 201-11. (IVT, NEW)

Jeon, Y., et al. "Beta-lapachone suppresses non-small cell lung cancer proliferation through the regulation of specificity Protein 1." *Biol. Pharm. Bull*. 2015; 38(9): 1302-8. (IVT, NEW)

Kung, H., et al. "Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells." *PLoS One*. 2014 Feb; 9(2): e88122. (IVT, NEW)

Larsson, D., et al. "Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines." *Anticancer Res*. 2006 Nov-Dec; 26(6B): 4125-9. (IVT, NEW)

Woo, H., et al. "Growth inhibition of A549 human lung carcinoma cells by beta-lapachone through induction of apoptosis and inhibition of telomerase activity." *Int. J. Oncol*. 2005; 26(4): 1017-23. (IVT)

Melanoma:

Shankar, B., et al. "Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2." *PLoS One*. 2018 Feb; 13(2): e0191419.

Kee, J., et al. "β-Lapachone suppresses the lung metastasis of melanoma via the MAPK signaling pathway." *PLoS One*. 2017 May; 12(5): e0176937. (IVA, IVT, NEW)

Bang, W., et al. "β-lapachone suppresses the proliferation of human malignant melanoma cells by targeting specificity protein 1." *Oncol Rep*. 2016 Feb; 35(2): 1109-16. (IVT, NEW)

Maeda, M., et al. "Promotion or suppression of experimental metastasis of B16 melanoma cells after oral administration of lapachol." *Toxicol. Appl. Pharmacol*. 2008 Jun; 229(2): 232-8. (IVA, IVT, NEW)

Multiple Myeloma:

Lima, K., et al. "Anticancer potential and safety profile of β -lapachone *in vitro*." *Molecules*. 2024; 29(6): 1395. (IVT)

Youzhi, Li., et al. "Selective killing of cancer cells by β -lapachone: Direct checkpoint activation as a strategy against cancer." *PNAS*. 2003 Mar; 100(5): 674–2678. (IVT, INS)

Gupta, D., et al. "Beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells." *Exp. Hematol*. 2002 Jul; 30(7): 711-20. (IVT, NEW)

Youzhi, Li., et al. "Potent induction of apoptosis by β -lapachone in human multiple myeloma cell lines and patient cells." *Mol. Med*. 2000 Dec; 6(12): 1008–1015. (IVT)

Pancreatic Cancer:

Qadir, M., et al. " β -lapachone: A promising anticancer agent with a unique NQO1 specific apoptosis in pancreatic cancer." *Curr. Cancer Drug Targets*. 2022; 22(7): 537-540. (REV)

Zheng, Y., et al. "X-ray repair cross-complementing protein 1 (XRCC1) loss promotes β -lapachone-induced apoptosis in pancreatic cancer cells." *BMC Cancer*. 2021 Nov; 21(1): 1234.

Beg, M., et al. "Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer." *J. Surg. Oncol*. 2017 Jul; 116(1): 83-88. (IVT, NEW)

Moore, Z., et al. "NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β -lapachone." *Cell Death Dis*. 2015 Jan; 6(1): e1599. (IVT, NEW)

Ough, M., et al. "Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1." *Cancer Biol. Ther*. 2005 Jan; 4(1): 95-102. (IVA, IVT)

Prostate Cancer:

Wu, X., et al. "Assessment of various formulation approaches for the application of beta-lapachone in prostate cancer therapy." *Int. J. Pharm*. 2020 Apr; 579: 119168. (REV)

Lee, J., et al. "Down-regulation of cyclooxygenase-2 and telomerase activity by beta-lapachone in human prostate carcinoma cells." *Pharmacol. Res*. 2005; 51(6): 553-60. (IVT, NEW)

Kumi-Diaka, J., et al. "Potential mechanism of phytochemical-induced apoptosis in human prostate adenocarcinoma cells: Therapeutic synergy in genistein and beta-lapachone combination treatment." *Cancer Cell Int*. 2004 Aug; 4(1): 5. (IVT)

Choi, Y., et al. "Suppression of human prostate cancer cell growth by beta-lapachone via down-regulation of PRB phosphorylation and induction of Cdk Inhibitor p21(WAF1/CIP1)." *J. Biochem. Mol. Biol*. 2003 Mar; 36(2): 223-9. (IVT, NEW)

Planchon, S., et al. "Beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3." *Exp. Cell. Res*. 2001 Jul; 267(1): 95-106. (IVT)

Reducing Chemotherapy Side Effects:

Kalantary-Charvadeh, A., et al. "β-lapachone protects against doxorubicin-induced hepatotoxicity through modulation of NAD⁺/SIRT-1/FXR/p-AMPK/NF-κB and Nrf2 signaling axis." *J. Biochem. Mol. Toxicol.* 2024 Jan; 38(1): e23564. **(IVA, NEW)**

Sanajou, D., et al. "β-Lapachone protects against doxorubicin-induced nephrotoxicity via NAD⁺/AMPK/NF-κB in mice." *Naunyn Schmiedebergs Arch. Pharmacol.* 2024 Jul; 397(7): 5331-5332. **(IVA, NEW)**

Lin, S., et al. "Mitochondrial activity is the key to the protective effect of β-Lapachone, a NAD⁺ booster, in healthy cells against cisplatin cytotoxicity." *Phytomedicine.* 2022 Jul; 101: 154094. **(IVA, IVT, NEW)**

Yarmohammadi, F., et al. "Natural compounds against doxorubicin-induced cardiotoxicity: A review on the involvement of Nrf2/ARE signaling pathway." *Phytother. Res.* 2021 Mar; 35(3): 1163-1175. **(REV)**

Nazari, S., et al. "β-lapachone ameliorates doxorubicin-induced cardiotoxicity via regulating autophagy and Nrf2 signalling pathways in mice." *Basic Clin. Pharmacol. Toxicol.* 2020 Apr; 126(4): 364-373. **(IVA, NEW)**

Sanajou, D., et al. "β-Lapachone protects against doxorubicin-induced nephrotoxicity via NAD⁺/AMPK/NF-κB in mice." *Naunyn Schmiedebergs Arch. Pharmacol.* 2019 May; 392(5): 633-640. **(IVA, NEW)**

Boriollo, M., et al. "Reduction of doxorubicin-induced genotoxicity by *Handroanthus impetiginosus* in mouse bone marrow revealed by micronucleus assay." *Braz. J. Biol.* 2018 Feb; 78(1): 1-12.

Kim, T., et al. "β-Lapachone enhances Mre11-Rad50-Nbs1 complex expression in cisplatin-induced nephrotoxicity." *Pharmacol. Rep.* 2016 Feb; 68(1): 27-31. **(IVA, NEW)**

Increasing Chemotherapy/Radiation Efficacy:

Ahn, K., et al. "Enhancement of radiation effect using beta-lapachone and underlying mechanism." *Radiat. Oncol. J.* 2013 Jun; 31(2): 57-65. **(IVT, NEW)**

Park, M., et al. "β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells." *PLoS One.* 2011; 6(10): e25976. **(IVT, NEW)**

Dong, G., et al. "Beta-lapachone suppresses radiation-induced activation of nuclear factor-κappaB." *Exp. Mol. Med.* 2010 May; 42(5): 327-34. **(IVT, NEW)**

Suzuki, M., et al. "Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells *in vitro*." *Radiat. Res.* 2006; 165(5): 525-31. **(IVT, NEW)**

Park, H., et al. "Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation." *Int. J. Radiat. Oncol. Biol. Phys.* 2005 Jan; 61(1): 212-9. **(IVA, IVT)**

Mechanisms of Action:

Preethi, S., et al. "Review on NAD(P)H dehydrogenase quinone 1 (NQO1) pathway." *Mol. Biol. Rep.* 2022 Sep; 49(9): 8907-8924.

Tahara, T., et al. "STAT3 inhibitory activity of naphthoquinones isolated from *Tabebuia avellanedae*." *Bioorg. Med. Chem.* 2020 Mar; 28(6): 115347. (IVT, INS, NEW)

Sun, X., et al. "Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway." *Cell Cycle.* 2006 Sep; 5(17): 2029-35. (IVT)

Li, Y., et al. "Selective killing of cancer cells by beta -lapachone: Direct checkpoint activation as a strategy against cancer." *Proc. Natl. Acad. Sci.* 2003 Mar; 100(5): 2674-8. (IVT)

Li, C., et al. Beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin." *J. Biol. Chem.* 1993 Oct; 268(30): 22463-8. (IVT)

New Drug Development:

Beta-Lapachone:

Li, Y., et al. "Beta-Lapachone nanomedicines for cancer-specific therapy." *Adv. Healthc. Mater.* 2023 Aug; 12(20): e2300349.

Gong, Q., et al. "A carbon-carbon bond cleavage-based prodrug activation strategy applied to β -Lapachone for cancer-specific targeting. *Angew. Chem. Int. Ed. Engl.* 2022 Oct; 61(40): e202210001.

Wu, L., et al. "Synthesis and biological evaluation of β -lapachone-monastrol hybrids as potential anticancer agents." *Eur. J. Med. Chem.* 2020 Oct; 203: 112594.

Li, S., et al. "Potent cytotoxicity of novel L-shaped ortho-quinone analogs through inducing apoptosis." *Molecules.* 2019 Nov; 24(22): 4138.

Ríos-Luci, C., et al. " β -Lapachone analogs with enhanced antiproliferative activity." *Eur. J. Med. Chem.* 2012 Jul; 53: o264-74.

Reinicke, K., et al. "Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels." *Clin. Cancer Res.* 2005 Apr; 11(8): 3055-64.

Krishnan, P., et al. "Novel mechanism of cellular DNA topoisomerase II inhibition by the pyranonaphthoquinone derivatives alpha-lapachone and beta-lapachone." *Cancer Chemother. Pharmacol.* 2001 Mar; 47(3): 187-98.

Lapachol:

de Andrade Borges, A., et al. "Determination of inhibitory effect of PKM2 enzyme and antitumoral activity of novel coumarin-naphthoquinone hybrids." *Curr. Med. Chem.* 2025; 32(2): 359-379.

Rissate, F., et al. "In vitro antitumor and antimetastatic activity of a new lapachol derivative against metastatic breast carcinoma." *Asian Pac. J. Cancer Prev.* 2024 Nov; 25(11): 3935-3946.

Stocchetti, S., et al. "Strong *in vitro* anticancer activity of copper(ii) and zinc(ii) complexes containing naturally occurring lapachol: cellular effects in ovarian A2780 cells." *RSC Med. Chem.* 2024 Sep; 15(12): 4180–92.

Mendes, S., et al. "Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model." *Biomed. Pharmacother.* 2021 Jan; 133: 110936.

Eyong, K., et al. "Semisynthesis and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone derivatives from lapachol." *Bioorg. Med. Chem. Lett.* 2008 Oct; 18(20): 5387-90.

Alpha-lapachone:

Mancini, I., et al. "Hybrid molecules containing naphthoquinone and quinolinedione scaffolds as antineoplastic agents." *Molecules.* 2022 Aug; 27(15): 4948.

Guimarães, D., et al. "Naphthoquinone-based hydrazone hybrids: synthesis and potent activity against cancer cell lines." *Med. Chem.* 2021; 17(9): 945-955.

Watson, R., et al. "Iron (III) chloride catalyzed formation of 3,4-Dihydro-2H-pyrans from α -Alkylated 1,3-Dicarbonyls: Selective synthesis of α - and β -lapachone." *Org. Lett.* 2016 Mar; 18(6): 1310-3.

Wei, P., et al. "New potential inhibitors of DNA topoisomerase. Part II: Design and synthesis of alpha-lapachone derivatives under microwave irradiation." *Bioorg. Med. Chem. Lett.* 2009 Feb; 19(3): 828-30.

Renou, S., et al. "Monoarylhydrazones of alpha-lapachone: synthesis, chemical properties and antineoplastic activity." *Pharmazie.* 2003 Oct; 58(10): 690-5.

Nor-beta-lapachone and Nor-alpha-lapachone:

Wu, L., et al. "Design, synthesis, and biological evaluation of 3-(1-benzotriazole)-nor- β -lapachones as NQO1-directed antitumor agents." *Bioorg. Chem.* 2021 Aug; 113: 104995.

da Silva, J., et al. "Synthesis and potent antitumor activity of new arylamino derivatives of nor-beta-lapachone and nor-alpha-lapachone." *Bioorg. Med. Chem.* 2007 Nov; 15(22): 7035-41.

NSC 95397 (2,3-bis-[2-hydroxyethylsulfanyl]-[1,4]naphthoquinone):

Jemaà, M., et al. "Stimulation of suicidal erythrocyte death by the CDC25 inhibitor NSC-95397." *Cell. Physiol. Biochem.* 2016; 40(3-4): 597-607.

Dubey, N., et al. "NSC 95397 suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and the ERK1/2 pathway." *Int. J. Mol. Sci.* 2018 May; 19(6): 1625.

Larsson, D., et al. "The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors *in vitro*." *Anticancer Res.* 2010 Jan; 30(1): 149-56.

Peyregne, V., et al. "Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties." *Mol. Cancer Ther.* 2005 Apr; 4(4): 595-602.

Brisson, M., et al. "Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase." *Mol. Pharmacol.* 2004 Oct; 66(4): 824-33.

BBI608 Napabucasin:

Wang, L., et al. "Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy." *Biomaterials.* 2025 Feb; 313: 122766. (IVT, IVA)

Shao, Z., et al. "The anticancer effect of napabucasin (BBI608), a natural naphthoquinone." *Molecules.* 2023 Jul; 28(15): 5678.

Bekaii-Saab, T., et al. "Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: An adaptive multicentre, randomised, open-label, phase 3, superiority trial." *EClinicalMedicine.* 2023 Mar; 58: 101897.

Shah, M., et al. "Napabucasin Plus FOLFIRI in patients with previously treated metastatic colorectal cancer: Results from the open-label, randomized Phase III CanStem303C study." *Clin. Colorectal Cancer.* 2023 Mar; 22(1): 100-110.

Kawazoe, A., et al. Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors." *Cancer Chemother. Pharmacol.* 2020; 85: 855–862.

Nagaraju, G., et al. "Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer." *Cancer.* 2020 Jul; 126(14): 3360-3371.

Han, D., et al. "Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells." *J. Exp. Clin. Cancer Res.* 2019 Jul; 38(1): 289.

Jonker, D., et al. "Napabucasin versus placebo in refractory advanced colorectal cancer: A randomised phase 3 trial." *Lancet Gastroenterol. Hepatol.* 2018 Apr; 3(4): 263-270.

Hubbard, J., et al. "An update on the first-in-class cancer stemness inhibitor." *Drugs.* 2017 Jul; 77(10): 1091-1103.

Mason, W., et al. "BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM)." *J. Clin. Oncol.* 2017; 35: e13525.

Grothey, A., et al. "CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC)." *J. Clin. Oncol.* 2017; 35: Suppl 15.

Becerra, C., et al. "Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma." *J. Clin. Oncol.* 2015; 33: 4069.